{"id":"bdp-hfa","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nervousness"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Throat irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Beclomethasone dipropionate (BDP) is a corticosteroid delivered via hydrofluoroalkane (HFA) propellant in metered-dose inhaler form. It acts locally in the airways to suppress inflammatory responses, reduce mucus production, and decrease airway hyperresponsiveness. The HFA formulation provides improved lung deposition compared to older chlorofluorocarbon (CFC) propellants.","oneSentence":"BDP HFA is a inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:51.465Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT01577082","phase":"PHASE3","title":"Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04-20","conditions":"Asthma","enrollment":542},{"nctId":"NCT05898984","phase":"PHASE1","title":"Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-04-24","conditions":"Asthma","enrollment":69},{"nctId":"NCT01615874","phase":"PHASE2","title":"Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT03084718","phase":"PHASE2","title":"An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-07-28","conditions":"Asthma","enrollment":610},{"nctId":"NCT01024608","phase":"PHASE3","title":"Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-12-31","conditions":"Seasonal Allergic Rhinitis, Hay Fever","enrollment":340},{"nctId":"NCT00988247","phase":"PHASE3","title":"Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-10-31","conditions":"Rhinitis, Allergic, Perennial","enrollment":529},{"nctId":"NCT02031640","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":1113},{"nctId":"NCT02040779","phase":"PHASE3","title":"A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12-26","conditions":"Persistent Asthma","enrollment":273},{"nctId":"NCT02040766","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":628},{"nctId":"NCT01343745","phase":"PHASE2","title":"Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2008-02","conditions":"Mild Persistent Asthma","enrollment":18},{"nctId":"NCT01280175","phase":"PHASE1","title":"Foster With or Without Charcoal Block or Aerochamber Plus","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2006-12","conditions":"Healthy Volunteers","enrollment":13},{"nctId":"NCT01848769","phase":"PHASE2","title":"Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-09","conditions":"Asthma","enrollment":20},{"nctId":"NCT00829257","phase":"PHASE4","title":"Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2009-01","conditions":"Asthma","enrollment":15},{"nctId":"NCT00921921","phase":"PHASE4","title":"Does Extra-fine Hydrofluoroalkane-beclomethasone Dipropionate (HFA-BDP) Suppress Small Airways Inflammation in Chronic Obstructive Pulmonary Disease (COPD)?","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2009-06","conditions":"COPD","enrollment":16},{"nctId":"NCT03503994","phase":"NA","title":"Inhaled Corticosteroids for Treatment of Bronchopulmonary Dysplasia","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2001-07-27","conditions":"Bronchopulmonary Dysplasia","enrollment":41},{"nctId":"NCT00862394","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-02","conditions":"Asthma","enrollment":783},{"nctId":"NCT00528723","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2007-11","conditions":"Bronchial Asthma","enrollment":180},{"nctId":"NCT00862264","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-08","conditions":"Asthma","enrollment":286},{"nctId":"NCT00868023","phase":"PHASE2","title":"Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-02","conditions":"Asthma","enrollment":69},{"nctId":"NCT01584492","phase":"PHASE2","title":"Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-12","conditions":"Asthma","enrollment":59},{"nctId":"NCT00659048","phase":"PHASE3","title":"Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Rhinitis, Allergic, Perennial","enrollment":106},{"nctId":"NCT01307319","phase":"PHASE3","title":"Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2011-03","conditions":"Seasonal Allergic Rhinitis, SAR","enrollment":715},{"nctId":"NCT01620099","phase":"PHASE4","title":"Small Airways Involvement in Smoker Asthmatic Patients: a Pilot Study","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2011-11","conditions":"Asthma","enrollment":60},{"nctId":"NCT01287351","phase":"","title":"Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2004-01","conditions":"Asthma","enrollment":82903},{"nctId":"NCT01141439","phase":"","title":"Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2001-01","conditions":"Asthma","enrollment":815377},{"nctId":"NCT01729351","phase":"","title":"Qvar Therapy in Smoking Asthmatics","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2011-11","conditions":"Asthma, Smoking","enrollment":7195},{"nctId":"NCT01400217","phase":"","title":"Qvar Versus Clenil, a General Practice Research Database Study","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"1991-01","conditions":"Asthma","enrollment":56985},{"nctId":"NCT01697722","phase":"","title":"Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination Therapy","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"1991-01","conditions":"Asthma","enrollment":815377},{"nctId":"NCT01133626","phase":"PHASE3","title":"Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-06","conditions":"Perennial Allergic Rhinitis","enrollment":107},{"nctId":"NCT01134705","phase":"PHASE3","title":"Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-05","conditions":"Rhinitis, Allergic, Perennial","enrollment":474},{"nctId":"NCT00854360","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-03","conditions":"Seasonal Allergic Rhinitis, Hayfever","enrollment":487},{"nctId":"NCT01537692","phase":"PHASE1","title":"Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-03","conditions":"Allergic Rhinitis","enrollment":30},{"nctId":"NCT01141452","phase":"","title":"Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2001-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":815377}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) Nasal Aerosol","QNASL®"],"phase":"phase_3","status":"active","brandName":"BDP HFA","genericName":"BDP HFA","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BDP HFA is a inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}